Ashland (ASH) Stock Analysis & Forecast

Last earnings call, Apr 28, 2026 AI summary

What they said

Ashland's Q2 FY2026 call presented a mixed but resilient operational picture: revenue was essentially flat year-over-year at $482 million (+1%), adjusted EBITDA declined 9% to $98 million (adjusted EPS $0.91, excluding intangible amortization), and adjusted EBITDA margin contracted ~220 basis points to ~20%. Management emphasized resilient demand in Life Sciences (notably injectables, tablet coatings, high-purity excipients) and Personal Care (biofunctional actives, microbial protection), while Specialty Additives and Intermediates experienced mixed market conditions. Results were materially impacted by internal, discrete operational disruptions—primarily the Calvert City outage (now resolved) and Hopewell HEC scale-up/productivity issues—plus some weather-related events and a discrete bad debt reserve in Specialty Additives. Foreign exchange provided a meaningful tailwind (~$16 million). Cash generation was a bright spot: operating cash flow was $50 million (up from $9 million prior year) and ongoing free cash flow $29 million, with liquidity of ~$939 million and net debt just over $1 billion. Management highlighted strong innovation momentum across three platform areas (transformed vegetable oil, super wetting agents, bioresorbable polymers) and reiterated the Globalize and Innovate strategic pillars driving share gains. They described active pricing and surcharge programs being implemented region- and product-by-product to offset rising feedstock and freight costs (management estimates ~20% of sales are energy/petchem/freight exposed, with cost increases concentrated in a 10–15% range on that basket). Management took a conservative view on the outlook given macro uncertainty and internal operating issues but noted upside potential from pricing realization and any demand tightening that increases pricing power and availability-driven share gains. Q&A focused on price/cost dynamics (magnitude and timing of price realization vs. raw material inflation), specifics and magnitude of the one-time operational impacts (management cited roughly $30 million of discrete impact across Calvert, Hopewell, and weather), Hopewell ramp-up root causes (mix change and productivity shortfall), Middle East geopolitical exposure (limited direct exposure but customer credit and demand impacts noted), and the sustainability of recent innovate/globalize wins. Management was candid about frustrations with internal operational failures but confident about remediation plans and the competitiveness of the portfolio.

Guidance

Revised full-year adjusted EBITDA guidance: $385 million to $400 million. Management described sales scenarios tied to guidance: lower end implies low single-digit year-over-year sales growth (largely driven by pricing actions and flattish volumes), higher end implies roughly 6%–7% sales growth balanced across volume and price. Management also noted ongoing pricing actions expected to begin flowing through starting this month, but they did not explicitly include realized pricing upside in the guidance due to macro uncertainty.

Risks flagged

Operational disruptions (Calvert City equipment failure/absorption impact; Hopewell HEC scale-up productivity issues; weather-related manufacturing disruptions); demand softness/ordering-timing in select non-pharma nutrition and construction end markets; discrete customer credit risk and bad debt reserve related to a Middle East energy customer; macro/geopolitical volatility in the Middle East impacting regional demand and credit; EV project delays impacting Intermediates; lag between raw material inflation and contractual pricing realization; targeted share gain pricing actions that could be resisted by customers.